Literature DB >> 10837639

Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions.

.   

Abstract

The development of long-circulating, RES-avoiding liposomes has become a remarkable milestone in the progress of contemporary pharmacology. Drugs incorporated in such liposomes are protected from fast metabolization and clearance, and can be further targeted to a desired tissue site. Ideally, future developments should result in drug carriers which can identify and act upon their targets with even higher efficiency and selectivity, preferably close to or exceeding that of the natural immune cells.Further increasing carrier 'inertness' with regard to the normal biological milieu is the major requirement for future success. The ability of natural blood components to circulate with blood for several days and weeks presents both the motivation and the challenge for further research. Today, even the best available preparations are inferior to natural proteins and cells with regard to their ability to remain in circulation by approximately two orders of magnitude.In view of the above, it seems vitally important to determine the mechanisms responsible for glycolipid- or polymer-modified liposome protection against RES, and whether any potentially useful mechanisms have been underutilized. Furthermore, identification of quantitative dependencies between liposome structure and pharmacokinetics (and mechanisms underlying such dependencies) would benefit future research and reduce the cost of development.This paper discusses the relationships between liposome structure and circulation with respect to the theoretical mechanistic models of mass transfer, liposome interactions with cells and blood proteins, and boundary effects resulting from surface modification. Special attention is paid to the practical application and limitations of the models.

Entities:  

Year:  1998        PMID: 10837639     DOI: 10.1016/s0169-409x(97)00135-x

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  15 in total

1.  Semisynthetic hydrophilic polyals.

Authors:  Mikhail I Papisov; Alexander Hiller; Alexander Yurkovetskiy; Mao Yin; Marlene Barzana; Shawn Hillier; Alan J Fischman
Journal:  Biomacromolecules       Date:  2005 Sep-Oct       Impact factor: 6.988

2.  Fully degradable hydrophilic polyals for protein modification.

Authors:  Alexander Yurkovetskiy; Sungwoon Choi; Alexander Hiller; Mao Yin; Catherine McCusker; Sakina Syed; Alan J Fischman; Mikhail I Papisov
Journal:  Biomacromolecules       Date:  2005 Sep-Oct       Impact factor: 6.988

3.  Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.

Authors:  Steven K Libutti; Giulio F Paciotti; Adriana A Byrnes; H Richard Alexander; William E Gannon; Melissa Walker; Geoffrey D Seidel; Nargiza Yuldasheva; Lawrence Tamarkin
Journal:  Clin Cancer Res       Date:  2010-09-27       Impact factor: 12.531

4.  Metallic Nanoparticles for Cancer Immunotherapy.

Authors:  Emily Reiser Evans; Pallavi Bugga; Vishwaratn Asthana; Rebekah Drezek
Journal:  Mater Today (Kidlington)       Date:  2017-12-14       Impact factor: 31.041

5.  Preparation and characterization of stable pH-sensitive vesicles composed of α-tocopherol hemisuccinate.

Authors:  Huan Xu; Yi-Hui Deng; Kai-Qian Wang; Da-Wei Chen
Journal:  AAPS PharmSciTech       Date:  2012-10-03       Impact factor: 3.246

6.  Halothane, a novel solvent for the preparation of liposomes containing 2-4'-amino-3'-methylphenyl benzothiazole (AMPB), an anticancer drug: a technical note.

Authors:  Yingqing Ran; Samuel H Yalkowsky
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

Review 7.  Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.

Authors:  Julia Y Ljubimova; Manabu Fujita; Alexander V Ljubimov; Vladimir P Torchilin; Keith L Black; Eggehard Holler
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

8.  In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content.

Authors:  Yan Sheng; Yuan Yuan; Changsheng Liu; Xinyi Tao; Xiaoqian Shan; Feng Xu
Journal:  J Mater Sci Mater Med       Date:  2009-04-14       Impact factor: 3.896

9.  Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles.

Authors:  Stephanie E A Gratton; Patrick D Pohlhaus; Jin Lee; Ji Guo; Moo J Cho; Joseph M Desimone
Journal:  J Control Release       Date:  2007-06-02       Impact factor: 9.776

10.  Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery.

Authors:  Dawei Gao; Shengnan Tang; Qi Tong
Journal:  Int J Nanomedicine       Date:  2012-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.